Status | Study |
Recruiting |
Study Name: Rituximab in Recurrent IgA Nephropathy Condition: Recurrent IgA Nephropathy Date: 2015-10-06 Interventions: Drug: Intravenous Rituximab - |
Completed |
Study Name: Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy Condition: IgA Nephropathy Date: 2015-08-17 Interventions: Biological: blood sample dosage of anti-hinge region antibodies |
Suspended |
Study Name: Effect of Tonsillectomy on Longterm Renal Outcome of IgA Nephropathy Condition: IgA Nephropathy Date: 2015-05-19 Interventions: Procedure: tonsillectomy The t |
Recruiting |
Study Name: Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Condition: IgA Nephropathy Date: 2014-08-30 Interventions: Drug: Losartan Losartan potass |
Active, not recruiting |
Study Name: BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration Condition: IgA Nephropathy Date: 2014-02-12 Interventions: Drug: Blisibimod Drug: Placebo |
Withdrawn |
Study Name: BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Condition: IgA Nephropathy Date: 2014-01-29 Interventions: Drug: Blisibimod Blisibimod ad |
Completed |
Study Name: IgA Nephropathy, Lymphocyte Homing and IgA Class Switch Condition: IgA Nephropathy Date: 2013-01-18 Interventions: Other: blood test |
Completed |
Study Name: Probiotics in IgA Nephropathy Condition: IgA Nephropathy Date: 2013-01-16 Interventions: Dietary Supplement: ProTectis Dietary Supp |
Active, not recruiting |
Study Name: Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Condition: IgA Nephropathy Date: 2012-12-12 Interventions: Drug: prednisone plus cyclophosphamide |
Completed |
Study Name: The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease Condition: Primary IgA Nephropathy Date: 2012-07-25 Interventions: Drug: NEFECON All patients wil |